



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

**#53621**

**Date:** November 27, 2023

**Subject:** Aeglea BioTherapeutics, Inc. – Name/Symbol Change  
Option Symbol: AGLE1  
New Symbol: SYRE1  
Date: 11/28/2023

Aeglea BioTherapeutics, Inc. (AGLE) will change its name and trading symbol to Spyre Therapeutics, Inc. (SYRE) effective November 28, 2023. As a result, option symbol AGLE1 will also change to SYRE1 effective at the opening of business on November 28, 2023.

Strike prices and all other option terms will not change. Clearing Member input to OCC must use the new option symbol SYRE1 commencing November 28, 2023.

**Date:** November 28, 2023

**Option Symbol:** AGLE1 changes to SYRE1 (AGLE options were adjusted on September 8, 2023. See OCC Information Memo #53146)

**Underlying Security:** AGLE changes to SYRE

**Contract Multiplier:** 1

**Strike Divisor:** 1

**New Multiplier:** 100

**Deliverable Per Contract:** 4 Spyre Therapeutics, Inc. (SYRE) Common Shares

**CUSIP:** 00773J202

**Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).